Buruli (Bairnsdale) ulcer in the setting of long-term adalimumab treatment for Crohn disease

Intern Med J. 2018 May;48(5):603-604. doi: 10.1111/imj.13788.

Authors

Julia Freckelton¹, Darcy Holt², Manjeet Sandhu³, Lani Prideaux³, Gregory T Moore^{1

3}

Affiliations

¹ School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.
² Clinical Nutrition and Metabolism Unit, Monash Health, Melbourne, Victoria, Australia.
³ Department of Gastroenterology, Monash Health, Melbourne, Victoria, Australia.

PMID: 29722190
DOI: 10.1111/imj.13788

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adalimumab / administration & dosage
Adalimumab / adverse effects*
Adult
Anti-Inflammatory Agents / administration & dosage
Anti-Inflammatory Agents / adverse effects
Buruli Ulcer / diagnosis*
Buruli Ulcer / etiology*
Buruli Ulcer / immunology
Crohn Disease / diagnosis
Crohn Disease / drug therapy*
Crohn Disease / immunology
Female
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / adverse effects
Mycobacterium ulcerans / drug effects
Mycobacterium ulcerans / isolation & purification*
Time Factors
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Anti-Inflammatory Agents
Immunosuppressive Agents
Tumor Necrosis Factor-alpha
Adalimumab